RxDoctor Payments Data

Tina Hill

Family · Honaker, VANPI 1851757058

Payments from drug & device makers

$642in general payments, 2019–2025

Across 37 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$235
  • AstraZeneca$202
  • Lilly USA, LLC$57
  • AbbVie$38
  • Axsome Therapeutics, Inc.$35
  • Phathom Pharmaceuticals, Inc.$26
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$642 in reported general payments places this provider in the 60th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$115,850
Medicare patients
201
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$144,746
EliquisApixaban152$122,674
TrulicityDulaglutide73$85,820
JanuviaSitagliptin Phosphate99$77,688
OzempicSemaglutide61$71,266
JardianceEmpagliflozin43$40,649
Diclofenac Sodium48$34,615
LinzessLinaclotide37$29,286
UbrelvyUbrogepant21$20,899
VascepaIcosapent Ethyl48$20,192
FarxigaDapagliflozin Propanediol22$13,556
RybelsusSemaglutide14$12,956
InvokanaCanagliflozin16$12,313
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$11,854
MyrbetriqMirabegron23$10,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$57$230,566190 claims
Novo NordiskOzempic, Rybelsus$235$84,22275 claims
AbbVieLinzess, Ubrelvy, Synthroid$38$53,670129 claims
AstraZenecaFarxiga, Symbicort, Nexium$202$22,39458 claims
Johnson & JohnsonInvokana$13$12,31316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,332 family providers in Virginia.

Other family in Honaker

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →